Portfolio Rapha Capital Management

Marker Therapeutics, Inc.: TapImmune And Marker Therapeutics Announce Successful Closing Of Previously Announced Merger And Financing

By Kevin SlawinOctober 17, 2018February 4th, 2021No Comments

Marker Therapeutics, Inc.
TapImmune And Marker Therapeutics Announce Successful Closing Of Previously Announced Merger And Financing
October 17, 2018

Previous PostAngelMD Portfolio Company Raydiant Oximetry Awarded FDA Breakthrough Device Status
Next PostPoseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma

© 2024 Ponce Therapeutics. Privacy Policy | Terms & Conditions